It should be kept in mind, however, that the predictive value of TMB has been shown to be applicable in tumors in which the neoantigen load was proportional with cytotoxic CD8+ levels in TME, implying that this is not a unique predictive biomarker of ICI efficacy across all tumor types [55]. Here, CD8A is linked to neoplasm.